Clinical trials roundup in idiopathic inflammatory myopathies

Current Opinion in Rheumatology

Volumn 23, Issue 6, 2011, Pages 605-611

  Mann, Heřman F ^a   Vencovsky, Jiří ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Anti TNF; Glucocorticoids; Myositis; Rituximab; Treatment

Indexed keywords

ALEMTUZUMAB; COLCHICINE; CYCLOSPORIN; DEXAMETHASONE; DILTIAZEM; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PAMIDRONIC ACID; PREDNISOLONE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SIGNAL RECOGNITION PARTICLE; TACROLIMUS; THALIDOMIDE; TOCILIZUMAB; TUMOR NECROSIS FACTOR; WARFARIN;

ANTISYNTHETASE SYNDROME; BACTERIAL INFECTION; CALCINOSIS; CLINICAL TRIAL (TOPIC); DERMATOMYOSITIS; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; ESOPHAGUS DISEASE; HUMAN; IDIOPATHIC DISEASE; IMMUNOSUPPRESSIVE TREATMENT; INCLUSION BODY MYOSITIS; INFECTION; LOW DRUG DOSE; MESENCHYMAL STEM CELL TRANSPLANTATION; MULTIPLE CYCLE TREATMENT; MYCOBACTERIOSIS; MYOSITIS; NONHUMAN; PILOT STUDY; POLYMYOSITIS; PRIORITY JOURNAL; RASH; RELAPSE; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODIES, NEOPLASM; CLINICAL TRIALS AS TOPIC; DERMATOMYOSITIS; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MESENCHYMAL STEM CELL TRANSPLANTATION; MYOSITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 82955189819     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32834ba787     Document Type: Review

References (62)

1. Oddis CV, Rider LG, Reed AM, et al. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 2005; 52:2607-2615. (Pubitemid 41369088)
2. Seshadri R, Feldman BM, Ilowite N, et al. The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis. Arthritis Rheum 2008; 59:989-995. (Pubitemid 351990996)
3. van de Vlekkert J, Hoogendijk JE, de Haan RJ, et al. Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial. Neuromuscul Disord 2010; 20:382-389.
4. Bandelier C, Guerne PA, Genevay S, et al. Clinical experience with mycophenolate mofetil in systemic autoimmune conditions refractory to common immunosuppressive therapies. Swiss Med Wkly 2009; 139:41-46.
5. Morganroth PA, Kreider ME, Werth VP. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res (Hoboken) 2010; 62:1496-1501.
6. Rouster-Stevens KA, Morgan GA, Wang D, Pachman LM. Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res 2010; 62:1446-1451.
7. Dagher R, Desjonquères M, Duquesne A, et al. Mycophenolate mofetil in juvenile dermatomyositis: a case series. Rheumatol Int 2010. [Epub ahead of print]
8. Lange U, Piegsa M, Müller-Ladner U, Strunk J. Anti-Jo-1 antibody positive polymyositis-successful therapy with leflunomide. Autoimmunity 2006; 39:261-264. (Pubitemid 43879040)
9. Boswell JS, Costner MI. Leflunomide as adjuvant treatment of dermatomyositis. J Am Acad Dermatol 2008; 58:403-406.
10. Sangle VS, Sangle SR, D'Cruz DP. Leflunomide as a remission-maintaining therapy in difficult-to-treat dermatomyositis. Ann Rheum Dis 2008; 67:723. (Pubitemid 351571942)
11. Gensburger D, Kawashima M, Marotte H, et al. Lupus erythematosus with leflunomide: induction or reactivation? Ann Rheum Dis 2005; 64:153-155. (Pubitemid 40075297)
12. Gómez Rodríguez N, Zulaica Garate A. Development of dermatomyositis in a woman with rheumatoid arthritis treated with leflunomide. An Med Interna 2005; 22:300-301. (Pubitemid 41133981)
13. Ochi S, Taniguchi K, Nagashima M. Leflunomide-induced polymyositis in a patient with rheumatoid arthritis. Mod Rheumatol 2009; 19:443-446.
14. Oddis CV, Sciurba FC, Elmagd KA, Starzl TE. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 1999; 353:1762-1763. (Pubitemid 29240378)
15. Wilkes MR, Sereika SM, Fertig N, et al. Treatment of antisynthetase- associated interstitial lung disease with tacrolimus. Arthritis Rheum 2005; 52:2439-2446. (Pubitemid 41117430)
16. Guglielmi S, Merz TM, Gugger M, et al. Acute respiratory distress syndrome secondary to antisynthetase syndrome is reversible with tacrolimus. Eur Respir J 2008; 31:213-217.
17. Waite LE, Madhok R. Tacrolimus: a potential therapy for polymyositis? Rheumatology (Oxford) 2009; 48:858-859.
18. Ando M, Miyazaki E, Yamasue M, et al. Successful treatment with tacrolimus of progressive interstitial pneumonia associated with amyopathic dermatomyositis refractory to cyclosporine. Clin Rheumatol 2010; 29:443-445.
19. Yamada A, Ohshima Y, Omata N, et al. Steroid-sparing effect of tacrolimus in a patient with juvenile dermatomyositis presenting poor bioavailability of cyclosporine A. Eur J Pediatr 2004; 163:561-562. (Pubitemid 39222512)
20. Martín Nalda A, Modesto Caballero C, Arnal Guimeral C, et al. Efficacy of tacrolimus (FK-506) in the treatment of recalcitrant juvenile dermatomyositis: study of 6 cases. Med Clin (Barc) 2006; 127:697-701.
21. Hassan J, van der Net JJ, van Royen-Kerkhof A. Treatment of refractory juvenile dermatomyositis with tacrolimus. Clin Rheumatol 2008; 27:1469-1471.
22. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329:1993-2000. (Pubitemid 24015043)
23. Barbasso Helmers S, Dastmalchi M, Alexanderson H, et al. Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies. Ann Rheum Dis 2007; 66:1276-1283. (Pubitemid 47492468)
24. Marie I, Menard JF, Hatron PY, et al. Intravenous immunoglobulins for steroidrefractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients. Arthritis Care Res (Hoboken) 2010; 62:1748-1755.
25. Danieli MG, Calcabrini L, Calabrese V, et al. Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis. Autoimmun Rev 2009; 9:124-127.
26. Danieli MG, Pettinari L, Moretti R, et al. Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun Rev 2011; 10:144-149.
27. Kim S, El-Hallak M, Dedeoglu F, et al. Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment. Arthritis Rheum 2009; 60:1825-1830.
28. Miyamae T, Sano F, Ozawa R, et al. Efficacy of thalidomide in a girl with inflammatory calcinosis, a severe complication of juvenile dermatomyositis. Pediatr Rheumatol Online J 2010; 8:6.
29. Slimani S, Abdessemed A, Haddouche A, et al. Complete resolution of universal calcinosis in a patient with juvenile dermatomyositis using pamidronate. Joint Bone Spine 2010; 77:70-72.
30. Marco Puche A, Calvo Penades I, Lopez Montesinos B. Effectiveness of the treatment with intravenous pamidronate in calcinosis in juvenile dermatomyositis. Clin Exp Rheumatol 2010; 28:135-140.
31. Vandenbroucke E, Grutters JC, Altenburg J, et al. Rituximab in life threatening antisynthetase syndrome. Rheumatol Int 2009; 29:1499-1502.
32. Sultan SM, Ng KP, Edwards JC, et al. Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy. Clin Exp Rheumatol 2008; 26:887-893.
33. Arlet JB, Dimitri D, Pagnoux C, et al. Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscul Disord 2006; 16:334-336.
34. Whelan BR, Isenberg DA. Poor response of anti-SRP-positive idiopathic immune myositis to B-cell depletion. Rheumatology (Oxford) 2009; 48:594-595.
35. Valiyil R, Casciola-Rosen L, Hong G, et al. Rituximab therapy for myopathy associated with antisignal recognition particle antibodies: a case series. Arthritis Care Res (Hoboken) 2010; 62:1328-1334.
36. Frikha F, Rigolet A, Behin A, et al. Efficacy of rituximab in refractory and relapsing myositis with anti-Jo1 antibodies: a report of two cases. Rheumatology (Oxford) 2009; 48:1166-1168.
37. Majmudar S, Hall HA, Zimmermann B. Treatment of adult inflammatory myositis with rituximab: an emerging therapy for refractory patients. J Clin Rheumatol 2009; 15:338-340.
38. Rios Fernández R, Callejas Rubio JL, et al. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies: a report of 4 cases and review of the literature. Clin Exp Rheumatol 2009; 27:1009-1016.
39. Lutt JR, Pisculli ML, Weinblatt ME, et al. Severe nontuberculous mycobacterial infection in 2 patients receiving rituximab for refractory myositis. J Rheumatol 2008; 35:1683-1685.
40. Sem M, Molberg O, Lund MB, Gran JT. Rituximab treatment of the antisynthetase syndrome: a retrospective case series. Rheumatology (Oxford) 2009; 48:968-971.
41. Mahler EA, Blom M, Voermans NC, et al. Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology (Oxford) 2011. doi:10.1093/rheumatology/ker088. [Epub ahead of print]
42. Couderc M, Gottenberg JE, Mariette X, et al. Efficacy and tolerance of rituximab in refractory idiopathic inflammatory myopathy. Data of the AIR Registry (abstract). Arthritis Rheum 2010; 62 (Suppl 10):S380.
43. Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis (DM) and adult polymyositis (PM): the RIM study (abstract). Arthritis Rheum 2010; 62:3844.
44. Rider LG, Giannini EH, Brunner HI, et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004; 50:2281-2290. (Pubitemid 38924407)
45. De Bleecker JL, Meire VI, Declercq W, Van Aken EH. Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies. Neuromuscul Disord 1999; 9:239-246. (Pubitemid 29287259)
46. Stübgen JP. Tumor necrosis factor-alpha as a potential therapeutic target in idiopathic inflammatory myopathies. J Neurol 2011; 258:961-970.
47. Efthimiou P. Tumor necrosis factor-alpha in inflammatory myopathies: pathophysiology and therapeutic implications. Semin Arthritis Rheum 2006; 36:168-172. (Pubitemid 44691885)
48. Riley P, McCann LJ, Maillard SM, et al. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) 2008; 47:877-880. (Pubitemid 351796377)
49. Hengstman GJ, De Bleecker JL, et al. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol 2008; 59:159-163. (Pubitemid 351301260)
50. Dastmalchi M, Grundtman C, Alexanderson H, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008; 67:1670-1677.
51. Coyle K, Pokrovnichka A, French K, et al. A randomized, double-blind, placebo-controlled trial of infliximab in patients with polymyositis and dermatomyositis (abstract). Arthritis Rheum 2008; 58 (Suppl):S923-S924.
52. The Muscle Study Group. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 2011. doi: 10.1002/ana.22477. [Epub ahead of print]
53. Ishikawa Y, Yukawa N, Ohmura K, et al. Etanercept-induced anti-Jo-1-antibody- positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature. Clin Rheumatol 2010; 29:563-566.
54. Klein R, Rosenbach M, Kim EJ, et al. Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol 2010; 146:780-784.
55. Brunasso AM, Scocco GL, Massone C. Dermatomyositis during adalimumab therapy for rheumatoid arthritis. J Rheumatol 2010; 37:1549-1550.
56. Narazaki M, Hagihara K, Shima Y, et al. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxford) 2011;50:1344-1346.
57. Bilgic H, Ytterberg SR, Amin S, et al. Interleukin-6 and type I interferonregulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 2009; 60:3436-3446.
58. Okiyama N, Sugihara T, Iwakura Y, et al. Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin- 17A. Arthritis Rheum 2009; 60:2505-2512.
59. Dorph C, Dastmalchi M, Alexanderson H, et al. Anakinra in patients with refractory idiopathic inflammatory myopathies (abstract). Arthritis Rheum 2009; 60 (Suppl 10):589.
60. Zong M, Malmström V, Lundberg IE. Anakinra effects on T cells in patients with refractory idiopathic inflammatory myopathies. Ann Rheum Dis 2011; 70 (Suppl 2):A80-A81.
61. Dalakas MC, Rakocevic G, Schmidt J, et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 2009; 132:1536-1544.
62. Wang D, Zhang H, Cao M, et al. Efficacy of allogeneic mesenchymal stem cell transplantation in patients with drug-resistant polymyositis and dermatomyositis. Ann Rheum Dis 2011; 70:1285-1288.